Skip to main content
. Author manuscript; available in PMC: 2022 Jun 7.
Published in final edited form as: Sci Immunol. 2022 Jun 3;7(72):eabn0175. doi: 10.1126/sciimmunol.abn0175

Fig. 2. IL-25 promotes intestinal tumors and tumor ILC2s.

Fig. 2

(A) Schematic of rIL-25 or vehicle treatment in Apc1322T/+ mice, where mice were injected three times per week for eight weeks. (B) Number of tumors in vehicle and rIL-25-treated Apc1322T/+ mice (vehicle, n = 7; rIL-25, n = 9). (C) Tumor ILC2 frequency in vehicle and rIL-25-treated Apc1322T/+ mice (vehicle, n = 7; rIL-25, n = 8). (D) Frequency of tumor infiltrating Th1 and CD8+ T cells in vehicle and rIL-25-treated Apc1322T/+ mice (vehicle, n = 7; rIL-25, n = 8). (E and F) Number of tumors and average tumor size (Il25+/+, n = 36; Il25tom/tom, n = 37) (E) and survival (F) of Il25+/+ and Il25tom/tom Apc1322T/+ mice. (G) Frequency of tumor ILC2s (Il25+/+, n = 17; Il25tom/tom, n = 15) from Il25+/+ and Il25tom/tom Apc1322T/+ mice. (H and I) Frequency of M-MDSCs and G-MDSCs (Il25+/+, n = 9; Il25tom/tom, n = 17) (H), and Th2 cells (Il25+/+, n = 10; Il25tom/tom, n = 11) (I), from Il25+/+ and Il25tom/tom Apc1322T/+ mice. Data pooled from two or more independent experiments and error bars show mean ± SEM. Statistical significance determined by unpaired two-tailed t-test, except in (F) by two-sided log-rank test. n.s. non-signifiacnt, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.